<p>MannKind Corporation (NASDAQ:MNKD - 获取免费报告) 的股价在周一下跌了 6.6%，因为华尔街 Zen 将该股票的评级从买入下调至持有。该股票最低交易价为 3.03 美元，最后交易价为 3.0650 美元。在午盘交易中，约有 1,435,401 股被交易，较日均交易量 5,144,097 股下降了 72%。该股票之前的收盘价为 3.28 美元。</p>
<p>MNKD 已经成为其他多篇报告的主题。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 MannKind 股票的 “持有（c）” 评级。Leerink Partners 在 11 月 13 日的研究报告中开始覆盖 MannKind 股票。他们对该股票设定了 “跑赢大盘” 的评级和 7.00 美元的目标价。加拿大皇家银行在周五的研究报告中重申了 “行业表现” 的评级，并将 MannKind 股票的目标价设定为 3.50 美元（从 7.50 美元下调）。Truist Financial 在 11 月 24 日的研究报告中对 MannKind 股票设定了 9.00 美元的目标价。最后，HC Wainwright 在 2 月 25 日的报告中重新发布了 “买入” 评级，并将 MannKind 股票的目标价设定为 11.00 美元。一位投资分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 9.21 美元。</p>
<p><strong>查看我们关于 MNKD 的最新股票报告</strong></p>
<h2>MannKind 的内部买卖</h2>
<p>在其他 MannKind 新闻中，内部人士 Stuart A. Tross 在 1 月 8 日的交易中出售了 47,006 股公司的股票。股票以平均价格 6.33 美元出售，总价值为 297,547.98 美元。交易后，该内部人士直接持有 985,007 股公司股票，价值约为 6,235,094.31 美元。这代表其持股比例下降了 4.55%。该交易在向证券交易委员会提交的文件中披露，文件可通过此链接访问。此外，首席执行官 Michael Castagna 在 12 月 17 日的交易中出售了 65,804 股公司的股票。股票以平均价格 6.01 美元出售，总交易额为 395,482.04 美元。交易后，首席执行官直接持有 2,504,792 股公司股票，价值为 15,053,799.92 美元。该交易使其持股比例下降了 2.56%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士出售了价值 1,546,840 美元的 262,846 股公司股票。公司内部人士持有公司股票的 2.70%。</p>
<h2>机构投资者对 MannKind 的看法</h2>
<p>几家对冲基金最近对该公司的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 MannKind 的持仓增加了 19.8%。AQR Capital Management LLC 目前持有 55,333 股该生物制药公司的股票，价值 278,000 美元，此前在该期间内又购买了 9,160 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 MannKind 的持仓增加了 3.0%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 210,565 股该生物制药公司的股票，价值 1,059,000 美元，此前在该期间内又收购了 6,079 股。瑞银资产管理美国有限公司的一个独立业务部门在第一季度将其在 MannKind 的持仓增加了 8.6%。瑞银资产管理美国有限公司的一个独立业务部门目前持有 670,872 股该生物制药公司的股票，价值 3,374,000 美元，此前在该期间内又收购了 53,202 股。住友三井信托集团在第二季度收购了 MannKind 的新股份，价值约 42,000 美元。最后，德克萨斯州教师退休系统在第二季度将其在 MannKind 的持仓增加了 4.7%。德克萨斯州教师退休系统目前持有 77,726 股该生物制药公司的股票，价值 291,000 美元，此前在该期间内又购买了 3,506 股。机构投资者和对冲基金持有公司 49.55% 的股票。</p>
<h2>MannKind 股价下跌 6.7%</h2>
<p>该公司的 50 日移动平均线为 5.55 美元，200 日移动平均线为 5.37 美元。该股票的市值为 9.3994 亿美元，市盈率为 153.33，贝塔值为 0.84。</p>
<p>MannKind (NASDAQ:MNKD - 获取免费报告) 最近在 2 月 26 日宣布了其季度财报。这家生物制药公司报告季度每股收益为（0.05 美元），低于分析师的共识预期（0.01 美元）0.04 美元。该公司在本季度的收入为 1.1196 亿美元，而分析师预期为 9985 万美元。MannKind 的净利润率为 1.68%，股本回报率为负 11.12%。该公司的季度收入较去年同期增长了 45.8%。去年同期，该公司每股收益为 0.03 美元。作为一个整体，卖方分析师预计 MannKind Corporation 在当前财年将发布 0.1 美元的每股收益。</p>
<h2>MannKind 公司简介</h2>
<p>（获取免费报告）</p>
<p>MannKind Corporation 是一家生物制药公司，专注于吸入式治疗产品的开发和商业化。公司的核心业务围绕其专有的 Technosphere®药物递送平台，该平台旨在通过肺部给药实现小分子药物的快速吸收。MannKind 的主要产品 Afrezza®是一种吸入式胰岛素疗法，旨在为 1 型和 2 型糖尿病成人提供快速作用的替代传统注射胰岛素。</p>
<p>Afrezza 获得了美国的批准。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 MannKind</li>
<li>白银突破 100 美元：下一个 500 美元的飙升会来吗？（加入我们 3 月 4 日）</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>ATCX 拥有巴西最大的关键矿产组合之一！</li>
<li>美国的 1776 再次上演</li>
<li>我 70 岁，拥有 150 万美元：每年将 12 万美元转换为 Roth 是否明智，还是代价高昂的错误？（咨询顾问）</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 MannKind 吗？</h2>
<p>在考虑 MannKind 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 MannKind 并不在名单上。</p>
<p>虽然 MannKind 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

曼恩凯德生物医疗

<p>曼恩凯德生物医疗（NASDAQ:MNKD）的股票在 Wall Street Zen 将其评级从买入下调至持有后下跌了 6.6%。该股票最低交易价格为 3.03 美元，交易量显著下降。分析师的评级各不相同，其中有一项强烈买入、五项买入和三项持有，导致共识评级为 “适度买入”，目标价格为 9.21 美元。近期的内部销售和机构投资反映了市场对该公司的持续关注，该公司在最近的财报中报告收入增长了 45.8%</p>

<p>MannKind Corporation (NASDAQ:MNKD - Get Free Report)'s stock price was down 6.6% on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The stock traded as low as $3.03 and last traded at $3.0650. Approximately 1,435,401 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 5,144,097 shares. The stock had previously closed at $3.28.</p>
<div class="lb-trans"><p>MannKind Corporation (NASDAQ:MNKD - 获取免费报告) 的股价在周一下跌了 6.6%，因为华尔街 Zen 将该股票的评级从买入下调至持有。该股票最低交易价为 3.03 美元，最后交易价为 3.0650 美元。在午盘交易中，约有 1,435,401 股被交易，较日均交易量 5,144,097 股下降了 72%。该股票之前的收盘价为 3.28 美元。</p>
</div><p>MNKD has been the topic of a number of other reports. Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of MannKind in a research note on Thursday, January 22nd. Leerink Partners began coverage on shares of MannKind in a research report on Thursday, November 13th. They set an &#34;outperform&#34; rating and a $7.00 target price on the stock. Royal Bank Of Canada reaffirmed a &#34;sector perform&#34; rating and set a $3.50 price target (down from $7.50) on shares of MannKind in a research note on Friday. Truist Financial set a $9.00 price objective on shares of MannKind in a research note on Monday, November 24th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $11.00 price objective on shares of MannKind in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $9.21.</p>
<div class="lb-trans"><p>MNKD 已经成为其他多篇报告的主题。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 MannKind 股票的 “持有（c）” 评级。Leerink Partners 在 11 月 13 日的研究报告中开始覆盖 MannKind 股票。他们对该股票设定了 “跑赢大盘” 的评级和 7.00 美元的目标价。加拿大皇家银行在周五的研究报告中重申了 “行业表现” 的评级，并将 MannKind 股票的目标价设定为 3.50 美元（从 7.50 美元下调）。Truist Financial 在 11 月 24 日的研究报告中对 MannKind 股票设定了 9.00 美元的目标价。最后，HC Wainwright 在 2 月 25 日的报告中重新发布了 “买入” 评级，并将 MannKind 股票的目标价设定为 11.00 美元。一位投资分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 9.21 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on MNKD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MNKD 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling at MannKind</h2>
<div class="lb-trans"><h2>MannKind 的内部买卖</h2>
</div><p>In other MannKind news, insider Stuart A. Tross sold 47,006 shares of the company's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the transaction, the insider directly owned 985,007 shares in the company, valued at approximately $6,235,094.31. This represents a 4.55% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO Michael Castagna sold 65,804 shares of the company's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total transaction of $395,482.04. Following the transaction, the chief executive officer directly owned 2,504,792 shares in the company, valued at $15,053,799.92. The trade was a 2.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 262,846 shares of company stock worth $1,546,840 over the last 90 days. Company insiders own 2.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他 MannKind 新闻中，内部人士 Stuart A. Tross 在 1 月 8 日的交易中出售了 47,006 股公司的股票。股票以平均价格 6.33 美元出售，总价值为 297,547.98 美元。交易后，该内部人士直接持有 985,007 股公司股票，价值约为 6,235,094.31 美元。这代表其持股比例下降了 4.55%。该交易在向证券交易委员会提交的文件中披露，文件可通过此链接访问。此外，首席执行官 Michael Castagna 在 12 月 17 日的交易中出售了 65,804 股公司的股票。股票以平均价格 6.01 美元出售，总交易额为 395,482.04 美元。交易后，首席执行官直接持有 2,504,792 股公司股票，价值为 15,053,799.92 美元。该交易使其持股比例下降了 2.56%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士出售了价值 1,546,840 美元的 262,846 股公司股票。公司内部人士持有公司股票的 2.70%。</p>
</div><h2>Institutional Investors Weigh In On MannKind</h2>
<div class="lb-trans"><h2>机构投资者对 MannKind 的看法</h2>
</div><p>Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in shares of MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company's stock valued at $278,000 after purchasing an additional 9,160 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MannKind by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company's stock worth $1,059,000 after acquiring an additional 6,079 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of MannKind by 8.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company's stock worth $3,374,000 after acquiring an additional 53,202 shares during the period. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of MannKind in the second quarter worth approximately $42,000. Finally, Teacher Retirement System of Texas grew its holdings in MannKind by 4.7% in the second quarter. Teacher Retirement System of Texas now owns 77,726 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 3,506 shares during the period. Institutional investors and hedge funds own 49.55% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近对该公司的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 MannKind 的持仓增加了 19.8%。AQR Capital Management LLC 目前持有 55,333 股该生物制药公司的股票，价值 278,000 美元，此前在该期间内又购买了 9,160 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 MannKind 的持仓增加了 3.0%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 210,565 股该生物制药公司的股票，价值 1,059,000 美元，此前在该期间内又收购了 6,079 股。瑞银资产管理美国有限公司的一个独立业务部门在第一季度将其在 MannKind 的持仓增加了 8.6%。瑞银资产管理美国有限公司的一个独立业务部门目前持有 670,872 股该生物制药公司的股票，价值 3,374,000 美元，此前在该期间内又收购了 53,202 股。住友三井信托集团在第二季度收购了 MannKind 的新股份，价值约 42,000 美元。最后，德克萨斯州教师退休系统在第二季度将其在 MannKind 的持仓增加了 4.7%。德克萨斯州教师退休系统目前持有 77,726 股该生物制药公司的股票，价值 291,000 美元，此前在该期间内又购买了 3,506 股。机构投资者和对冲基金持有公司 49.55% 的股票。</p>
</div><h2>MannKind Stock Down 6.7%</h2>
<div class="lb-trans"><h2>MannKind 股价下跌 6.7%</h2>
</div><p>The business's fifty day moving average is $5.55 and its 200-day moving average is $5.37. The stock has a market capitalization of $939.94 million, a PE ratio of 153.33 and a beta of 0.84.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 5.55 美元，200 日移动平均线为 5.37 美元。该股票的市值为 9.3994 亿美元，市盈率为 153.33，贝塔值为 0.84。</p>
</div><p>MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.04). The company had revenue of $111.96 million during the quarter, compared to analyst estimates of $99.85 million. MannKind had a net margin of 1.68% and a negative return on equity of 11.12%. The firm's revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 EPS. As a group, sell-side analysts anticipate that MannKind Corporation will post 0.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MannKind (NASDAQ:MNKD - 获取免费报告) 最近在 2 月 26 日宣布了其季度财报。这家生物制药公司报告季度每股收益为（0.05 美元），低于分析师的共识预期（0.01 美元）0.04 美元。该公司在本季度的收入为 1.1196 亿美元，而分析师预期为 9985 万美元。MannKind 的净利润率为 1.68%，股本回报率为负 11.12%。该公司的季度收入较去年同期增长了 45.8%。去年同期，该公司每股收益为 0.03 美元。作为一个整体，卖方分析师预计 MannKind Corporation 在当前财年将发布 0.1 美元的每股收益。</p>
</div><h2>MannKind Company Profile</h2>
<div class="lb-trans"><h2>MannKind 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物制药公司，专注于吸入式治疗产品的开发和商业化。公司的核心业务围绕其专有的 Technosphere®药物递送平台，该平台旨在通过肺部给药实现小分子药物的快速吸收。MannKind 的主要产品 Afrezza®是一种吸入式胰岛素疗法，旨在为 1 型和 2 型糖尿病成人提供快速作用的替代传统注射胰岛素。</p>
</div><p>Afrezza received U.S.</p>
<div class="lb-trans"><p>Afrezza 获得了美国的批准。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MannKind</li>
<li>Silver Crossed $100: Is the $500 surge next? (Join us March 4)</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!</li>
<li>America’s 1776 happening again</li>
<li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 MannKind</li>
<li>白银突破 100 美元：下一个 500 美元的飙升会来吗？（加入我们 3 月 4 日）</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>ATCX 拥有巴西最大的关键矿产组合之一！</li>
<li>美国的 1776 再次上演</li>
<li>我 70 岁，拥有 150 万美元：每年将 12 万美元转换为 Roth 是否明智，还是代价高昂的错误？（咨询顾问）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MannKind Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 MannKind 吗？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MannKind 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 MannKind 并不在名单上。</p>
</div><p>While MannKind currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MannKind 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

曼恩凯德（NASDAQ:MNKD）股价在分析师下调评级后下跌了 6.6%